Arcturus Therapeutics (ARCT) Fundamental Analysis: Revenue, Earnings & Valuation

7.00 / 10

Outperform

Fundamental analysis rates ARCT at 7.0/10, citing strong accounts receivable turnover, interest coverage, PB‑ROE, and asset‑to‑market ratios. However, revenue fell 46% YoY and cost‑of‑sales is high, while income‑tax ratio is zero, creating mixed drivers but overall Outperform.

Analysis Checks(8/10)

Revenue-MV

Value-1.47

Score3/3

Weight30.42%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value-46.14

Score1/3

Weight-3.71%

1M Return-1.40%

Inventory turnover ratio

Value106.57

Score3/3

Weight-1.73%

1M Return-0.67%

Accounts receivable turnover ratio

Value17.20

Score2/3

Weight-1.71%

1M Return-0.65%

PB-ROE

Value-0.45

Score3/3

Weight44.01%

1M Return12.56%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-3.89%

1M Return-1.54%

Fixed assets turnover ratio

Value10.09

Score3/3

Weight2.28%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-1.93%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-1.89%

1M Return-0.74%

Asset-MV

Value-0.55

Score2/3

Weight38.16%

1M Return9.91%

Is ARCT undervalued or overvalued?

ARCT scores 7.00/10 on fundamentals and holds a Discounted valuation at present. Backed by its -28.92% ROE, -80.19% net margin, -2.92 P/E ratio, 0.90 P/B ratio, and 20.00% earnings growth, these metrics solidify its Outperform investment rating.